VTRS Profile
Viatris Inc. operates globally as a prominent healthcare company, focusing on four key segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company's extensive portfolio includes prescription brand drugs, generics, complex generics, biosimilars, and active pharmaceutical ingredients (APIs). Covering therapeutic areas ranging from noncommunicable diseases to oncology and immunology, Viatris offers a wide array of medications in oral solid doses, injectables, and other complex dosage forms.
In addition to its pharmaceutical offerings, Viatris provides comprehensive support services such as diagnostic clinics, educational seminars, and digital health tools aimed at enhancing patient care and health management. The company serves a diverse customer base that includes retail pharmacies, wholesalers, payers, insurers, governments, and institutional healthcare providers worldwide. Through strategic collaborations and licensing agreements with leading biopharmaceutical firms, Viatris continues to expand its product pipeline and bolster its presence in key therapeutic markets.
Established in 1961 and headquartered in Canonsburg, Pennsylvania, Viatris has built a legacy of delivering essential healthcare solutions globally. Known for brands like Lyrica, Lipitor, and EpiPen, as well as biosimilars such as Fulphila and Hulio, Viatris remains committed to advancing healthcare accessibility and affordability. With a strong emphasis on innovation and patient-centric care, Viatris strives to address critical healthcare challenges and improve outcomes for patients worldwide.
|
